Cargando…

Prognostic value of intratumoral metabolic heterogeneity on F-18 fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced cervical cancer patients treated with concurrent chemoradiotherapy

OBJECTIVE: To evaluate the prognostic value for predicting tumor recurrence of intratumoral metabolic heterogeneity and traditional quantitative metabolic parameters on pre-treatment F-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in patients with locally ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Chong, Gun Oh, Lee, Won Kee, Jeong, Shin Young, Park, Shin-Hyung, Lee, Yoon Hee, Lee, Sang-Woo, Hong, Dae Gy, Kim, Jae-Chul, Lee, Yoon Soon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685760/
https://www.ncbi.nlm.nih.gov/pubmed/29163839
http://dx.doi.org/10.18632/oncotarget.18769
_version_ 1783278682841808896
author Chong, Gun Oh
Lee, Won Kee
Jeong, Shin Young
Park, Shin-Hyung
Lee, Yoon Hee
Lee, Sang-Woo
Hong, Dae Gy
Kim, Jae-Chul
Lee, Yoon Soon
author_facet Chong, Gun Oh
Lee, Won Kee
Jeong, Shin Young
Park, Shin-Hyung
Lee, Yoon Hee
Lee, Sang-Woo
Hong, Dae Gy
Kim, Jae-Chul
Lee, Yoon Soon
author_sort Chong, Gun Oh
collection PubMed
description OBJECTIVE: To evaluate the prognostic value for predicting tumor recurrence of intratumoral metabolic heterogeneity and traditional quantitative metabolic parameters on pre-treatment F-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy (CCRT). MATERIALS AND METHODS: Ninety-three patients with biopsy-proven cervical cancer and treated with CCRT (FIGO stage IIB-IV) were enrolled in this study. The traditional metabolic parameters of the primary tumor, regional lymph node, and whole body (maximum standardized uptake value [SUVmax], metabolic tumor volume [MTV], and total lesion glycolysis), and intratumoral heterogeneity factor (HF) were measured on pre-treatment 18F-FDG PET/CT images. Univariate and multivariate analyses for disease-free survival (DFS) were performed using clinical and metabolic parameters. The additional HF prognostic value was evaluated by means of time-dependent receiver operating characteristic curve, integrated discrimination improvement, and net reclassification improvement. RESULTS: On multivariate analysis, nodal SUVmax (hazard ratio 3.60; 95% CI, 1.66–7.85; p = 0.0012) and whole body MTV (WBMTV; hazard ratio 3.15; 95% CI, 1.17–8.53; p = 0.0236) were significant prognostic factors for DFS. When HF was combined with nodal SUVmax and WBMTV, a significant improvement in discrimination for recurrence was observed compared with nodal SUVmax alone (area under curve 0.817 vs. 0.732; p = 0.0028). CONCLUSIONS: HF did not show superiority over traditional metabolic parameters. However, when HF was combined with nodal SUVmax and WBMTV, the predictive value for tumor recurrence improved. Therefore, HF may be a useful additional prognostic biomarker to improve the prognostic value of traditional metabolic parameters on 18F-FDG PET/CT.
format Online
Article
Text
id pubmed-5685760
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-56857602017-11-21 Prognostic value of intratumoral metabolic heterogeneity on F-18 fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced cervical cancer patients treated with concurrent chemoradiotherapy Chong, Gun Oh Lee, Won Kee Jeong, Shin Young Park, Shin-Hyung Lee, Yoon Hee Lee, Sang-Woo Hong, Dae Gy Kim, Jae-Chul Lee, Yoon Soon Oncotarget Clinical Research Paper OBJECTIVE: To evaluate the prognostic value for predicting tumor recurrence of intratumoral metabolic heterogeneity and traditional quantitative metabolic parameters on pre-treatment F-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy (CCRT). MATERIALS AND METHODS: Ninety-three patients with biopsy-proven cervical cancer and treated with CCRT (FIGO stage IIB-IV) were enrolled in this study. The traditional metabolic parameters of the primary tumor, regional lymph node, and whole body (maximum standardized uptake value [SUVmax], metabolic tumor volume [MTV], and total lesion glycolysis), and intratumoral heterogeneity factor (HF) were measured on pre-treatment 18F-FDG PET/CT images. Univariate and multivariate analyses for disease-free survival (DFS) were performed using clinical and metabolic parameters. The additional HF prognostic value was evaluated by means of time-dependent receiver operating characteristic curve, integrated discrimination improvement, and net reclassification improvement. RESULTS: On multivariate analysis, nodal SUVmax (hazard ratio 3.60; 95% CI, 1.66–7.85; p = 0.0012) and whole body MTV (WBMTV; hazard ratio 3.15; 95% CI, 1.17–8.53; p = 0.0236) were significant prognostic factors for DFS. When HF was combined with nodal SUVmax and WBMTV, a significant improvement in discrimination for recurrence was observed compared with nodal SUVmax alone (area under curve 0.817 vs. 0.732; p = 0.0028). CONCLUSIONS: HF did not show superiority over traditional metabolic parameters. However, when HF was combined with nodal SUVmax and WBMTV, the predictive value for tumor recurrence improved. Therefore, HF may be a useful additional prognostic biomarker to improve the prognostic value of traditional metabolic parameters on 18F-FDG PET/CT. Impact Journals LLC 2017-06-28 /pmc/articles/PMC5685760/ /pubmed/29163839 http://dx.doi.org/10.18632/oncotarget.18769 Text en Copyright: © 2017 Chong et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Clinical Research Paper
Chong, Gun Oh
Lee, Won Kee
Jeong, Shin Young
Park, Shin-Hyung
Lee, Yoon Hee
Lee, Sang-Woo
Hong, Dae Gy
Kim, Jae-Chul
Lee, Yoon Soon
Prognostic value of intratumoral metabolic heterogeneity on F-18 fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced cervical cancer patients treated with concurrent chemoradiotherapy
title Prognostic value of intratumoral metabolic heterogeneity on F-18 fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced cervical cancer patients treated with concurrent chemoradiotherapy
title_full Prognostic value of intratumoral metabolic heterogeneity on F-18 fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced cervical cancer patients treated with concurrent chemoradiotherapy
title_fullStr Prognostic value of intratumoral metabolic heterogeneity on F-18 fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced cervical cancer patients treated with concurrent chemoradiotherapy
title_full_unstemmed Prognostic value of intratumoral metabolic heterogeneity on F-18 fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced cervical cancer patients treated with concurrent chemoradiotherapy
title_short Prognostic value of intratumoral metabolic heterogeneity on F-18 fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced cervical cancer patients treated with concurrent chemoradiotherapy
title_sort prognostic value of intratumoral metabolic heterogeneity on f-18 fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced cervical cancer patients treated with concurrent chemoradiotherapy
topic Clinical Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685760/
https://www.ncbi.nlm.nih.gov/pubmed/29163839
http://dx.doi.org/10.18632/oncotarget.18769
work_keys_str_mv AT chonggunoh prognosticvalueofintratumoralmetabolicheterogeneityonf18fluorodeoxyglucosepositronemissiontomographycomputedtomographyinlocallyadvancedcervicalcancerpatientstreatedwithconcurrentchemoradiotherapy
AT leewonkee prognosticvalueofintratumoralmetabolicheterogeneityonf18fluorodeoxyglucosepositronemissiontomographycomputedtomographyinlocallyadvancedcervicalcancerpatientstreatedwithconcurrentchemoradiotherapy
AT jeongshinyoung prognosticvalueofintratumoralmetabolicheterogeneityonf18fluorodeoxyglucosepositronemissiontomographycomputedtomographyinlocallyadvancedcervicalcancerpatientstreatedwithconcurrentchemoradiotherapy
AT parkshinhyung prognosticvalueofintratumoralmetabolicheterogeneityonf18fluorodeoxyglucosepositronemissiontomographycomputedtomographyinlocallyadvancedcervicalcancerpatientstreatedwithconcurrentchemoradiotherapy
AT leeyoonhee prognosticvalueofintratumoralmetabolicheterogeneityonf18fluorodeoxyglucosepositronemissiontomographycomputedtomographyinlocallyadvancedcervicalcancerpatientstreatedwithconcurrentchemoradiotherapy
AT leesangwoo prognosticvalueofintratumoralmetabolicheterogeneityonf18fluorodeoxyglucosepositronemissiontomographycomputedtomographyinlocallyadvancedcervicalcancerpatientstreatedwithconcurrentchemoradiotherapy
AT hongdaegy prognosticvalueofintratumoralmetabolicheterogeneityonf18fluorodeoxyglucosepositronemissiontomographycomputedtomographyinlocallyadvancedcervicalcancerpatientstreatedwithconcurrentchemoradiotherapy
AT kimjaechul prognosticvalueofintratumoralmetabolicheterogeneityonf18fluorodeoxyglucosepositronemissiontomographycomputedtomographyinlocallyadvancedcervicalcancerpatientstreatedwithconcurrentchemoradiotherapy
AT leeyoonsoon prognosticvalueofintratumoralmetabolicheterogeneityonf18fluorodeoxyglucosepositronemissiontomographycomputedtomographyinlocallyadvancedcervicalcancerpatientstreatedwithconcurrentchemoradiotherapy